CellCentric expands in US with new Boston office

The move will increase the Chesterford Research Park company’s drug development capacity, progressing its novel drug treating multiple myeloma, inobrodib.

Located in Burlington, Boston, Massachusetts, the US presence will enhance the company’s ability to access talent and foster further clinical collaborations as it accelerates towards registration studies for its first-in-class oral drug.

CEO Will West said: “These are exciting times as we continue to grow, to deliver inobrodib as fast, effectively and maximally as possible, for the benefit of people with multiple myeloma.

“As we expand geographically and in scale, ensuring that we continue to work as one harmonised team will be key. We all have a responsibility on that front.”

Andy Fergus, Chief Development Officer at CellCentric, said: “Boston’s status as a global hub for biotechnology and pharmaceutical innovation makes it the ideal location to further advance inobrodib’s development.

“Our new office will serve as key additional hub for our international operations as we convene expertise from across the globe to address an unmet need in the multiple myeloma community.”

In conjunction with the office opening, CellCentric has strengthened its leadership significantly in recent months. The revised team has been involved with more than 50 per cent of all late-stage development and targeted market drugs for multiple myeloma.

Development is headed by Naseer Qayum, Chief Strategy Officer, ex-Roche, J&J and AbbVie, alongside Andy Fergus, ex-Takeda. Both have deep experience in seeing novel drugs to treat multiple myeloma through to registration.

Last year the company received significant investment from RA Capital before releasing promising efficacy and safety data at the American Society of Hematology (ASH) Annual Meeting.